Fairvalue-Calculator Fairvalue-Calculator
EN DE

Harvard Bioscience, Inc (HBIO) Fair Value & Analysis

Healthcare · US · Market cap $26.5M

Price$6.01
Fair Value$7.73
Upside+28.6%
Quality95/100
Evidence: Medium Range $4.65 – $13.04

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Harvard Bioscience, Inc (HBIO) currently trades at $6.01, while our model-based Fair Value estimate is $7.73 — implying the stock looks roughly 28.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous …

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -44% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44%

Frequently asked questions

Is Harvard Bioscience, Inc (HBIO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $7.73 versus a price of $6.01 — about +29% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HBIO?
Our 21-model fair value for Harvard Bioscience, Inc is $7.73 (as of Jun 24, 2026), built from audited fundamentals. The current price is $6.01.
What is the quality score of HBIO?
Harvard Bioscience, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.